Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Met een emissiekoers van €12,00 in juni 2015, een slotkoers van €10,20 in december 2015 en een slotkoers van €9,04 in december 2016 heeft Mithra het sinds de emissie niet goed gedaan voor beleggers. Operationeel gaat het wel goed. Met een fase II voor Donesta en fase III studies voor Estelle in Europa en Noord-Amerika. Als die studies goed uitpakken, kan de koers enorm omhoog. Fingers crossed!! fc
MITHRA’S NORTH AMERICAN ADVISORY BOARD FOR DONESTA® WILL MEET IN MIAMI, FLORIDA 20TH - 21ST JANUARY 2017 Mithra has set up scientific advisory boards composed of international experts to support the development of Donesta®, its product candidate for menopause based on Estetrol (E4). The North American scientific advisory board, set up by Mithra, is aiming at gathering additional development guidance from international experts in the menopause field. Liège, Belgium, 12 January 2017 – In order to support the development programme and to prepare its product candidate for a future introduction on the market, Mithra has set up a North American advisory committee. Composed of 7 acknowledged menopause experts from the USA and Canada, this committee will especially advise Mithra on the clinical relevance and the potential added value of E4 based product candidate for the treatment of vasomotor symptoms. The committee will work with Mithra to challenge the current and future development plan with the needs of the community at large. This meeting will be chaired by Prof. Jean-Michel Foidart, member of Mithra’s scientific committee. François Fornieri, CEO of Mithra Pharmaceuticals: “We are extremely proud that we have been able to bring top tier opinion leaders together to help us with our development plan which is a key objective for Mithra. The interest these international experts show in taking part in this meeting reflects the continuous and growing need for safe and effective solutions in the menopause field. We expect our product candidate will bring more choices to women and hope it will allow to address the unmet medical needs they are confronted with”. A second Pan-European advisory board meeting will be organized in Lisboa, Portugal in February 2017 to pursue this world market analysis and support the development plans in the EU.
Je vraagt je af wat er aan de hand is? Ik denk dat we eerdaags de Donesta phase II resultaten kunnen verwachten. De experts moeten toch ergens iets van vinden :). fc
Daarnaast, omdat Mithra relatief kort bestaat heb je nauwelijks hits op clinical trials. Als je echter Estetrol intypt komt er plotseling een hoop:clinicaltrials.gov/ct2/results?term=E... Zelfs een studie om te kijken wat Estetrol doet op een man. fc
MITHRA STRENGTHENS POSITION IN THE BELGIAN CONTRACEPTION MARKET Mithra builds on leading position in Belgian contraceptive market Mithra achieves significant increase in 2016 sales Market trend validates Mithra’s Estetrol-based programs Liège, Belgium January 31, 2017 - Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97% to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%. The Belgian contraception market grew by 2.01 % during 2016 or 229.389 cycles. In 2016, there were 17.645 more women using a contraceptive product, of these Mithra has captured 16.659 of the new patients, representing 94.4 % of the total growth of the market in 2016. Mithra remains largely in poleposition in terms of sold cycles with a significant growth of 4.23 % or +216.576 cyles. In 2016, over 410.500 women(almost 1 in every 2 women who takes an oral contraceptive) use a Mithra oral contraceptive product in Belgium. François Fornieri, CEO of Mithra Pharmaceuticals: "This leading position strengthens the credibility of Mithra on its own market, but also internationally, which is positive for our Estetrol-based R&D project in contraception which would present a lower VTE risk and an improved safety profile over currently available products."
Aandeel daalt enorm bij redelijk goed nieuws of was het niet goed genoeg ??? o0 Mithra is en blijft een bedrijf met zeer sterk potentieel begrijp niet waarom het nu zo hard naar beneden gaat de laatste 2 weken pff
Er was een wat grotere verkoper actief. Er lag al dagen een blok van 7000 tot 9000 aandelen op €10,20. Die zijn vanochtend gedumpt en dat gaf tijdelijk de prijsval tot €9,70. Krabbelt wel weer op. Aandeel is nog steeds onder de radar. fc
MITHRA COMPLETES REC RUITMENT FOR EUROPEAN PHASE III ESTELLE® STUDY Liège, Belgium, 07 February 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it has completed recruitment into the Phase III study of its product candidate Estelle®, a combined oral contraceptive based on Estetrol (E4) and Drospirenone (DRSP), in Europe and Russia. As of 6 February 2017, 1709 patients have been screened, of which it is expected that at least 1550 will qualify for enrollment in to the study which is designed to assess the safety and efficacy of Estelle® over the course of 12 months. Results of the European study are expected in H2 2018. A second Phase III study in the US and Canada started enrollment in September 2016. Francois Fornieri, CEO of Mithra Pharmaceuticals, said: “We are pleased to confirm the completion of patient enrollment into one of two pivotal studies for Estelle®. Initial studies have shown the potential advantages of Estetrol including a reduction in side effects such as the risk of venous Thromboembolism, an increase in body weight and undesired bleeding whilst on the pill. We are on track to complete the trial in 2018 and hope to be able to provide women globally with a novel contraceptive option with a better safety and efficacy profile compared to currently-available treatments.” European Phase III study design (Estelle®) The European Phase III Estelle® study design is an open-label single arm study that is expected to enroll at least 1550 patients aged 18-50 years of whom 1350 patients are aged 18-35 years. The objectives of the study are to evaluate the contraceptive’s efficacy, cycle control, and the general safety and acceptability of the 15mg estetrol (E4) and 3mg RSP combination oral contraceptive pill in healthy women aged 18-50 years old. The study is taking place in approximately 69 centres across Europe and Russia, and will involve patient enrollment for a period of 12 months (13 cycles, 1 cycle = 28 days). The primary outcome measures will be the number of pregnancies per 100 women per 12 months of exposure in patients aged 18 to 35 years old. The secondary outcomes will measure the on-treatment pregnancies within the overall study population (18-50 years), bleeding profile, safety and tolerability, general wellbeing of the patients (measured by two questionnaires) and any adverse impact on the endometrium. This last parameter will be evaluated based on 167 patients out of the expected 1550 enrolled.
Mijn positie op €9,89 bijna verdubbeld vandaag. Zo slecht was het nieuws toch niet gisteren. Er is duidelijk wat verkoopdruk de laatste dagen. Er lag een blok van ongeveer 20000 aandelen rond de €9,90 vandaag, die de koers fixeerde. Benieuwd of het aanbod nu weg is en of we weer wat omhoog kunnen!? fc
ingestapt vandaag deze morgen 500st op 10,1€ binnen enkele weken Donesta.... fingers crossed...
Hallo, Vanmorgen ingestapt! Ik dacht zal Marc Coucke zijn favoriet toch maar is inkopen en direct al 4procent er bij! Heeft al meer opgebracht dan bij men bank na een jaar! ??
en dit alles zonder nieuws....
De Donesta phase II komt er eerdaags aan, was gepland voor eind 2016 dus is al ietwat vertraagd. Daarnaast verwacht ik voor het eind van de maand februari een deal over Estelle met het Chinese bedrijf. Kortom, een paar belangrijke pers momenten. fc
FatCool schreef op 15 februari 2017 22:04 :
De Donesta phase II komt er eerdaags aan, was gepland voor eind 2016 dus is al ietwat vertraagd.
Daarnaast verwacht ik voor het eind van de maand februari een deal over Estelle met het Chinese bedrijf.
Kortom, een paar belangrijke pers momenten.
fc
idd, las ook ergens dat die Donesta nadert worden spannende dagen maw... :)
Hoop goed nieuws nog de komende dagen! Koers gaat soms nog wel is omlaag maar niet meer zoveel als paar maand geleden! Goed voortrekken !
Feb 28 (Reuters) - Mithra Pharmaceuticals SA MITRA.BR : * Mithra concludes exclusive license and supply agreement with Mayne Pharma for myring marketing in the United States * Under the terms of the agreement, Mayne Pharma will pay milestones of at least 10 million euros ($10.59 million) following approval by US (FDA) * Mithra will produce Myring for Mayne Pharma in its Research, Development and Production Center (Mithra CDMO) * Under the terms of the agreement, Mithra will receive 2.4 million euros upon signing Source text for Eikon: Further company coverage: ($1 = 0.9446 euros) (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;)) leuk toch? mag doorsijpelen naar de beurs....
Mithra Pharmaceuticals: AGREES EXCLUSIVE LONG-TERM LICENSE AND SUPPLY AGREEMENT WITH MAYNE PHARMA TO COMMERCIALIZE MYRING(TM) IN THE US 28 februari 2017 07:00 PRESS RELEASE Mithra agrees ExclusiveLONG-TERMlicense and supply agreement with Mayne Pharma to commercialize Myring(TM) in the US ? Mithra grants its first exclusive license for its vaginal contraception ring, Myring(TM), to Mayne Pharma (ASX: MYX), the second-largestsupplierof oral contraceptives in the USmarket, covering commercialization in the United States ? As part of the agreement, Mayne Pharma will pay milestones of at least EUR 10.0m following approval by the US FDA ? Mithra will produce Myring(TM) for MaynePharmaat its Research, Development and Manufacturing facility (Mithra CDMO) Liège, Belgium, 27 February 2017- Mithra Pharmaceuticals, a company dedicated to Women's Health, is pleased to announce an exclusive long-term license and supply agreement that extends beyond 10 years with Mayne Pharma, a leading specialty pharmaceutical company, for the commercialization in the United States of Myring(TM), Mithra's combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). Mayne Pharma is the second largest supplier of oral contraceptive products in the US market. Under the terms of the agreement, Mithra will receive EUR 2.4m upon signature, as well as significant milestone payments on ANDA approval (market approval by the FDA) and on the commercial launch of the product. As a part of Mayne Pharma's long-term exclusive sourcing commitment, Mithra is considering the expansion of its production capacity for Myring(TM). Currently, the US market for biocompatible contraceptive rings is worth EUR 740m [1] , which represents approximately 30% of the total global market by volume and over 75% by value, making this a key territory for the commercialization of Myring(TM). Mithra is anticipating important financial contributions from this product post-commercial launch, aligned with the market potential and Mayne Pharma's commitment to the oral contraceptive market. François Fornieri, CEO Mithra Pharmaceuticals:"This agreement with Mayne Pharma further demonstrates Mithra's attractiveness for partnerships, exemplifying our strategy to seek specialist partners around the world. It also underlines our expertise in polymers and proves the confidence that key US companies have in our know-how and the research and manufacturing capabilities of Mithra's CDMO. Furthermore, the attractive deal terms validate Mithra's acquisition of the remainder of Novalon in December 2015. Through the acquisition of a portfolio of 42 pharmaceutical products from Teva last year, Mayne Pharma became a top 25 retail generic pharmaceutical company with an extensive portfolio of women's health products. Hence, we strongly believe that we have the best partner at our side to market our vaginal ring, Myring (TM) , in the key US market." About Mayne Pharma Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company develops and manufactures branded and generic products globally - either directly or through distribution partners - while applying its drug-delivery expertise for contract development and manufacturing services. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and its technologies have been successfully commercialized in products marketed around the world. Mayne Pharma has drug development and manufacturing facilities in Greenville, North Carolina, USA, and Salisbury, Australia, and offers expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, and modified release products. In the United States, Mayne Pharma's operations consist of U.S. Generic Products, U.S. Specialty Brands, and Metrics Contract Services. About Myring(TM) Myring(TM) is developed to be a generic of Nuvaring® vaginal ring, still under patent protection up to April 2018 both in the US and in EU. Myring(TM) (etonogestrel/ethinyl estradiol vaginal ring) is a non-biodegradable, flexible, transparent, combination contraceptive vaginal ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It is made of ethylene vinylacetate copolymers, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases, in line with the originator (Nuvaring®), on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed.
Vanavond een positief persbericht over Donesta. Mithra Signs a Binding Term Sheet with the Japanese Leader in Women’s Health Fuji Pharma to Commercialize Donesta® in Japan and ASEAN. Door een uitbreiding van de phase II study is er een vertraging van deze studie tot eind Q1 2018. Maar uit het persbericht lees ik een uiterst positieve ontwikkeling van Donesta. fc
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)